drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A subcutaneous bispecific T‑cell–engaging monoclonal antibody (CD20×CD3) that binds CD20 on malignant B cells and CD3 on T cells to form an immune synapse, activating T cells to kill CD20+ B-ALL blasts via cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Mosunetuzumab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
CD20×CD3 bispecific antibody that simultaneously binds CD20 on malignant B cells and CD3 on T cells, forming an immune synapse that activates T cells via CD3/TCR signaling to lyse CD20+ B cells through cytotoxicity and cytokine release.
drug_name
Mosunetuzumab (RO7030816)
nct_id_drug_ref
NCT05961696